Pacific Biosciences is trading at $2.50, up 6.82%, with the gain supported by a broader biotech-sector advance.
- XBI rose 2.13% during the regular session.
- No clear company-specific catalyst was identified for November 3. Coverage focuses on Q3 results expected November 4; an earnings preview discusses expectations, not results driving the move.
- Volume details were not established.